Patient P-02409

Synthetic patientMETA-24 · Day 115 · 35–44 · M · baseline S01Steering view · 3D Open companion preview

Therapy response

Declining

Tolerance

Stable

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

62%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S01
Day 26 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 74 SC-12 recommended — Supportive Compound SC-12
Day 75 GI-04 recommended — GI Support Protocol GI-04
Day 75 Patient accepted — Started SC-12 in the companion
Day 76 Patient accepted — Started GI-04 in the companion
Day 81 No meaningful change — Supportive Compound SC-12
Day 84 No meaningful change — GI Support Protocol GI-04

What changed?

Trajectory began diverging from predicted response on Day 26.

Primary contributors, last 14 days

Treatment adherence-10
GI instability-4
Toxicity-4
Inflammatory activity-3
Nutritional resilience+3

What helped?

Supportive Compound SC-12Day 74
Result: no meaningful change
GI Support Protocol GI-04Day 75
Result: no meaningful change

LIFE OS recommendation

Monitoring Escalation ME-01

79%

probability of meaningful tolerance improvement

284 similar trajectories
100% showed improvement
median effect visible after 3 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes

Wearable

33 min

improving · +4.7 vs previous 14 d

Sleep duration

Wearable

6.4 h

stable · +0.1 vs previous 14 d

Energy level

Daily log

2.1/10

worsening · -0.3 vs previous 14 d

Steps

Wearable

3,289

improving · +576 vs previous 14 d

GI burden

Companion

59.3/100

stable · -0.7 vs previous 14 d

Adherence

Companion

54.9 %

worsening · -15.5 vs previous 14 d

Sleep quality

Wearable

20.5/100

improving · +2.1 vs previous 14 d

Glucose, CGM daily mean

CGM

138 mg/dL

stable · -3.1 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 31 from the failing basin, 64 from restoration.

Would help

ME-01 Monitoring Escalation
100% improved among 42 similar · onset 3 d · confidence 67%
NP-02 Dietary Support Protocol
59% improved among 32 similar · onset 10 d · confidence 67%
CR-01 Clinician Review
100% improved among 7 similar · onset 5 d · confidence 67%
More protein
GI -3 next day on high-intake days · n 20

Would not help

GI-04 GI Support Protocol
already tried, no meaningful change
SC-12 Supportive Compound
already tried, no meaningful change
Keep fat low
GI +3.8 next day on high-intake days · n 29
Keep fibre low
GI +3 next day on high-intake days · n 17

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Dietary fat load
+3.8detractor · 95%
Insoluble fibre
+3detractor · 94%
Protein
-3supporter · 95%
Histamine load
+1.7no signal · 51%
Ultra-processed food
+1.2no signal · 39%
Caffeine
+0.8no signal · 22%
Alcohol
-0.4no signal · 15%
Simple carbohydrates
+0.1no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 44/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↓65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 65
- WearableHRV 20 ms, trending down
Autonomic recovery ↑65
- WearableResting HR 88 bpm
- Wearable3,289 steps/day
- WearableShort sleep window
Mucosal barrier integrity ↓50
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 59 and rising
Drug metabolism and exposure ↑20
- BloodToxicity index 55

DNA

Fictional pharmacogenomic panel

IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure
GLP1R rs6923761 A
Altered receptor sensitivity
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 3 · butyrate capacity 44/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 17 ms
Sleep: 6.7 h
Steps: 3,354
Resting HR: 87 bpm

Daily log: GI score 59, nutritional resilience 39, adherence 55.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02483	20%	S06	BR-03	no change	64
P-02151	39%	S04	CR-01	improved	49
P-02025	33%	S15	CR-01	improved	61
P-02054	33%	S01	CR-01	improved	57
P-02009	28%	S08	CR-01	improved	64
P-02233	27%	S16	CR-01	improved	66
P-02154	24%	S16	CR-01	improved	57
P-02354	19%	S01	CR-01	improved	78
P-02395	20%	S12	DT-01	improved	57
P-02491	20%	S09	DT-01	no change	65
P-02274	19%	S15	DT-01	improved	50
P-02339	19%	S03	DT-01	improved	50